Anika Therapeutics Inc (NASDAQ:ANIK) Q4 2019 Earnings Conference Call - Final Transcript
Feb 20, 2020 • 05:00 pm ET
Good evening, ladies and gentlemen, and welcome to Anika Therapeutics Fourth Quarter and Full Year 2019 Earnings Conference Call. [Operator Instructions] After the speakers presentation, there will be a question-and-answer session. [Operator Instructions]
I will now turn the call over to Sylvia Cheung, Chief Financial Officer. Please proceed.
Thank you, Lide. Good evening, everyone and thank you for joining us. With me on the call today is Dr. Cheryl Blanchard, Interim Chief Executive Officer; and Jim Loerop, Executive Vice President of Business Development and Strategic Planning. During today's call, Cheryl, Jim and I will review our fourth quarter and full year 2019 financial results and key business highlights, which were summarized in our earnings release issued today. A copy of the earnings release is available on our Investor Relations section of our website at anikatherapeutics.com. In addition, a slide presentation is posted on our website in the Investor Relations section under the Events & Presentations tab.
We invite you to take a moment now to open a file and follow the presentation along with us. Please turn to Slide 2. Before we begin, please remember that certain statements made during this conference call constitute forward-looking statements as defined in the Securities and Exchange Act of 1934. These statements are based on our current beliefs and expectations and are subject to certain risks and uncertainties. The company's actual results could differ materially from any anticipated future results, performance or achievements. Please also see our SEC filings for more information about factors that could affect our results.
Certain financial measures we will discuss on this call are non-GAAP financial measures. We believe that these measures provide -- helps investors gain a more complete understanding of our results and is consistent with how management views our financial performance. A reconciliation of these non-GAAP financial results to the most comparable GAAP measurement, calculated and presented in accordance with US GAAP is available in the Investor Relations section of our website.
I will now turn the call over to our Interim CEO, Dr. Cheryl Blanchard. Cheryl?
Thank you, Sylvia and good evening, everyone. Before we discuss our financial results and outlook for the year ahead, I'd like to start by remembering Anika's President and CEO, Joe Darling, who passed away unexpectedly on January 29. When I interviewed to join Anika's Board, Joe talked about Anika and the people who make up Anika with a passion you hope every leader exhibits about his or her company. Joe was a wonderful leader and a trusted colleague, who led the beginning of our transformation into a global commercial company. Over the last 2.5 years, he set Anika on its current path reinforcing its strong foundation, leveraging its strengths and embracing innovation.
Most recently, he led the development of our five-year strategic plan, which will continue to guide our growth over the next several years. Joe was a great man with a well-deserved reputation in our industry for being a strong leader, who is passionate about healthcare. Though certainly we'll